Bayer And Morphosys Brush Off ADC Mesothelioma Failure

 
• By Alexandra Shimmings

A mid-stage trial of a Bayer/Morphosys antibody-drug conjugate for mesothelioma has failed, crossing one indication off the list of its potential uses, but development in other indications continues.

Anthophyllite asbestos
Asbestos In its raw form • Source: Shutterstock

More from Clinical Trials

More from R&D